Drug Trial Radar · NCT05682378
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
195
Planned (sponsor's estimate)
Start
Feb 10, 2023
Primary completion
Mar 25, 2032
Study completion Mar 28, 2032
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this open-label, single arm, multicenter extension study is to evaluate the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH who have completed the ORION-16 (CKJX839C12301), ORION-13 (CKJX839C12302), ORION-20 (CKJX839C12303) or ORION-19 (CKJX839C12304) studies.
Conditions
- Heterozygous or Homozygous Familial Hypercholesterolemia
Interventions
InclisiranDrug
Solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs)Time frame: From Day 1 in the study up to the end of study visit; up to 1080 days
Locations
52 sites in 26 countries. Site status is shown where the registry gives one.
Excel Medical Clinical Trials LLC
Boca Raton, Florida · Completed
Icahn School of Med at Mt Sinai
New York, New York · Active not recruiting
Cincinnati Childrens Hospital MC
Cincinnati, Ohio · Completed
Childrens Hosp Pittsburgh UPMC
Pittsburgh, Pennsylvania · Completed
Primary Childrens Medical Center
Salt Lake City, Utah · Recruiting
Novartis Investigative Site
Formosa, Formosa Province, Argentina · Active not recruiting
Novartis Investigative Site
Fortaleza, Ceará, Brazil · Active not recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Completed
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Active not recruiting
Novartis Investigative Site
Québec, Quebec, Canada · Active not recruiting
Novartis Investigative Site
Prague, Czechia · Active not recruiting
Novartis Investigative Site
Prague, Czechia · Active not recruiting
Novartis Investigative Site
Besançon, France · Active not recruiting
Novartis Investigative Site
Toulouse, France · Active not recruiting
Novartis Investigative Site
Freiburg im Breisgau, Germany · Completed
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany · Active not recruiting
Novartis Investigative Site
Athens, Greece · Completed
Novartis Investigative Site
Athens, Greece · Active not recruiting
Novartis Investigative Site
Pécs, Baranya, Hungary · Completed
Novartis Investigative Site
Jerusalem, Israel · Active not recruiting
Novartis Investigative Site
Ramat Gan, Israel · Active not recruiting
Novartis Investigative Site
Milan, MI, Italy · Completed
Novartis Investigative Site
Modena, MO, Italy · Completed
Novartis Investigative Site
Roma, RM, Italy · Completed
Novartis Investigative Site
Roma, RM, Italy · Active not recruiting
Novartis Investigative Site
Irbid, Jordan · Active not recruiting
Novartis Investigative Site
Beirut, Lebanon · Active not recruiting
Novartis Investigative Site
Beirut, Lebanon · Active not recruiting
Novartis Investigative Site
Kuala Lumpur, Malaysia · Active not recruiting
Novartis Investigative Site
Sungai Buloh, Selangor, Malaysia · Active not recruiting
Novartis Investigative Site
Amsterdam, North Holland, Netherlands · Active not recruiting
Novartis Investigative Site
Rotterdam, South Holland, Netherlands · Active not recruiting
Novartis Investigative Site
Oslo, Norway · Active not recruiting
Novartis Investigative Site
Gdansk, Poland · Active not recruiting
Novartis Investigative Site
Lodz, Łódź Voivodeship, Poland · Completed
Novartis Investigative Site
Kemerovo, Russia · Completed
Novartis Investigative Site
Moscow, Russia · Completed
Novartis Investigative Site
Poprad, Slovakia · Active not recruiting
Novartis Investigative Site
Ljubljana, Slovenia · Active not recruiting
Novartis Investigative Site
Bloemfontein, Free State, South Africa · Active not recruiting
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.